NAD+ dosage: chart, reported range and vial math
The range reported for injected NAD+ is 25 to 100 mg, one to three times a week. Every human study gave NAD+ into a vein, at doses from 10 mg a day to 750 mg per infusion. No study of injecting it under the skin was found. There is no approved NAD+ drug.
NAD+ dosage chart
Reported range, not a label dosePick your vial size. Each row shows the dose in milligrams or micrograms, the volume to draw and the mark on a U-100 syringe.
| Dose | Volume | Syringe units |
|---|---|---|
| 25 mg | 0.25 mL | 25 units |
| 50 mg | 0.50 mL | 50 units |
| 100 mg | 1.00 mL | 100 units |
Source Reported step-up, not a label dose: 25 to 50 mg in weeks 1 and 2, then 50 to 100 mg. Published human studies gave NAD+ into a vein. Vial math is arithmetic.
Which syringe fits each dose
For the 500 mg vial at 100 mg/mL.
| Dose | Volume | Units | 0.3 mL syringe | 0.5 mL syringe | 1 mL syringe |
|---|---|---|---|---|---|
| 25 mg | 0.25 mL | 25 units | Yes | Yes | Yes |
| 50 mg | 0.50 mL | 50 units | No | Yes | Yes |
| 100 mg | 1.00 mL | 100 units | No | No | Yes |
How long a vial lasts
Whole doses in one vial. The row for the size picked above is marked.
| Vial | 25 mg | 50 mg | 100 mg |
|---|---|---|---|
| 500 mg vial | 20 doses | 10 doses | 5 doses |
How to mix a NAD+ vial
These steps are for the 500 mg vial picked in the chart. Change the size there and the amounts here change with it.
- Wash your hands. Wipe the stopper of the peptide vial and the water vial with an alcohol swab.
- Draw 5 mL of bacteriostatic water into a syringe.
- Push the needle through the stopper of the peptide vial and let the water run slowly down the glass, not straight onto the powder.
- Swirl the vial gently until the powder is gone. Do not shake it.
- Write the date and 100 mg/mL on the vial, then put it in the fridge.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 500 mg vial | 5 mL | 100 mg/mL |
What NAD+ is
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, a pyridine nucleotide rather than a peptide, that cells use in energy metabolism. This page covers NAD+ itself given by infusion or injection, not the oral precursors NR and NMN. [1]
Other names: nicotinamide adenine dinucleotide, NAD.
How it has been given to people: intravenous infusion in every human study found; no human study of NAD+ injected under the skin or into muscle was found.
What to know before reading a dose
- Not an approved drug in the US or Canada as of the check date. Every dose on record is from one small study, one clinic record review or one hospital trial, and all three gave it by intravenous infusion.
- No human study of NAD+ injected under the skin or into muscle was found.
- A 2026 systematic review found no outcome trials of intravenous or intramuscular NAD+ for anti-aging or wellness [4]. A 2026 narrative review calls the evidence preliminary and insufficient to support routine clinical or wellness use [5].
- The doses on record are far apart: 10 mg a day in the heart failure trial against 500 mg and 750 mg per infusion in the two wellness-setting studies.
- The pharmacokinetic study was carried out at a wellness center that uses NAD+ infusions as a therapy, and the tolerability review used client records from a commercial setting [1], [2].
- Health Canada lists NAD+ among unauthorized injectable products it has seized [8].
Doses on record for NAD+
Every dose below was given in a human study or printed on an approved label, and each links to its source. Doses set by body weight are left that way.
| From | Where it was used | Dose | How often | For how long | Source |
|---|---|---|---|---|---|
| Human study | Pharmacokinetic pilot study; continuous intravenous infusion in normal saline over 6 hours (about 2 mg per minute), run at a wellness center in Louisiana | 750 mg | single infusion over 6 hours | one day | [1] |
| Human study | Retrospective review of client records from a commercial infusion provider, not a prospective trial; intravenous infusion in 500 mL saline, rate set by the client | 500 mg | once a day | 4 consecutive days | [2] |
| Human study | Single-center randomized placebo-controlled trial in China, added to standard heart failure treatment; intravenous | 10 mg | per day | 7 days | [3] |
What the evidence shows
Each finding is tagged by the kind of study it comes from. Human trials are listed first.
Randomized human trial
In a randomized placebo-controlled trial in 180 adults with heart failure, 7 days of intravenous NAD+ gave a larger improvement in ejection fraction at 1 month than placebo. Differences in clinical events over 6 months did not reach statistical significance. [3]
Randomized human trial
Oral precursors are a separate matter: in a 2026 systematic review, oral NR and NMN reliably raised NAD-related markers, but effects on health outcomes were mixed and often null. [4]
Small human study
During a 6-hour infusion in 8 healthy men, plasma NAD+ and its metabolites did not change until after the first 2 hours. [1]
Small human study
A 2026 narrative review found the human evidence on intravenous NAD+ to be sparse: mostly small uncontrolled studies, observational work and single case reports. [5]
Side effects and warnings
Reported in human studies or on a label:
- In a clinic record review, all 6 people given 500 mg NAD+ by infusion reported moderate to severe stomach and bowel symptoms, a faster heart rate and chest pressure during the infusion. The symptoms stopped when the infusion ended. [2]
- Because of those symptoms the NAD+ infusions were run more slowly, averaging 97 minutes against 37 minutes for nicotinamide riboside. [2]
- The 8-man pharmacokinetic study, with a slower 6-hour infusion, saw no adverse events. [1]
- A 2026 review lists nausea, cramping, flushing and chest discomfort as reported effects and says long-term safety data are lacking. [5]
NAD+ has no approved label in the US or Canada for this use, so there is no official list of who should not use it, no interaction list and no missed-dose rule.
Storage
Keep an unmixed vial the way its label says. Once it is mixed, keep it in the fridge, do not freeze it, and write the mixing date on the vial.
NAD+ dosage questions
How many units is 50 mg of NAD+ from a 500 mg vial?
Mixed with 5 mL of bacteriostatic water, a 500 mg vial is 100 mg/mL. 50 mg is 0.50 mL, which is 50 units on a U-100 syringe.
How much water goes in a 500 mg NAD+ vial?
5 mL gives 100 mg/mL. At that strength the doses in the chart sit at 25, 50, 100 units on a U-100 syringe.
How many doses are in a 500 mg vial?
Whole doses in one vial: 20 at 25 mg, 10 at 50 mg, 5 at 100 mg.
Is NAD+ approved in the US?
No FDA-approved NAD+ drug product. Nicotinamide Adenine Dinucleotide (NAD) is on FDA's 503A Category 1 list of bulk drug substances under evaluation for use in compounding.
Is NAD+ authorized in Canada?
No injectable NAD+ product in the Health Canada Drug Product Database. Health Canada names NAD+ among unauthorized injectable products it has seized, and a 2025 recall covered NAD+ solutions sold without market authorization.
What human dosing data is there for NAD+?
Not an approved drug in the US or Canada as of the check date. Every dose on record is from one small study, one clinic record review or one hospital trial, and all three gave it by intravenous infusion.
Sources
Each one was opened on 10 Oct 2026 and matched to the line it supports.
- Grant R et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci 2019. PubMed 31572171.
- Reyna K et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD(+)) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging 2026. PubMed 41704678.
- Yu X et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. Am J Cardiovasc Drugs 2026. PubMed 40954388.
- Gallagher C et al. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev 2026. PubMed 41655607.
- Alangari A et al. Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine. Front Aging 2026. PubMed 42787547.
- US Food and Drug Administration Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act 2026. fda.gov.
- US Food and Drug Administration Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act 2026. fda.gov.
- Health Canada Think twice before injecting peptides bought online: unauthorized products can seriously harm you 2026. recalls-rappels.canada.ca.
- Health Canada Skycare Compounding Laboratories Products recall; No market authorization 2025. recalls-rappels.canada.ca.
- Health Canada Health Canada Drug Product Database, active ingredient search: nad 2026. health-products.canada.ca.
- World Anti-Doping Agency The Prohibited List 2026. wada-ama.org.
Looked for and not found
- No human study of NAD+ given under the skin or into muscle. PubMed searches for subcutaneous or intramuscular NAD+ in humans returned no dosing study.
- No human half-life figure. The one pharmacokinetic study reports plasma levels during and 2 hours after a 6-hour infusion but gives no half-life.
- No approved label, so no official dose, contraindications, interaction list or storage instructions.
- The Health Canada Licensed Natural Health Products Database was not searched, so oral NAD or NADH supplements licensed in Canada are not covered here.
- Not named on the WADA Prohibited List (page checked 2026-10-10, [11]). The list also has an open class, S0, for substances with no current approval by any governmental health authority for human therapeutic use; whether it applies to this compound was not determined here.
Change log
10 Oct 2026Page published. 11 sources checked. Vial math added for the 500 mg vial.
Related
MOTS-c dosageEpitalon dosageSS-31 (elamipretide) dosageCardiogen dosageLivagen dosage500 mg vialWhat NAD+ isLongevityPeptide dosage chartDosage calculator
DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.